Recently Featured
Scientist working in a pharmaceutical lab

Nurix Stock Drops 38% as Sanofi Halts SAR448272 Development

November 9, 2026
Nurix Therapeutics suffered its worst one-day loss as a public company when Sanofi terminated development of the Phase I immunology candidate SAR448272 (NX-3911). This program was a key part of their nearly seven-year collaboration worth up to $2.5 billion to develop protein degradation drugs. Despite the termination, the collaboration continues. The trial for SAR448272 had…
scientists discussing heart disease study

Novartis Pelacarsen and Novo Nordisk IL-6 Drug Fail to Show Benefit

November 8, 2026
Novartis drug pelacarsen showed no effect on heart attack and stroke rates despite lowering lp(a) levels. This was highlighted in a study presented at the American Heart Association’s annual meeting. Similarly, a study from Novo Nordisk evaluating an anti-inflammatory targeting IL-6 also demonstrated no benefit. These findings raise questions about the reliability of new technologies…
Courtroom scene with legal documents

BIO Joins Legal Challenge Against Medicare Drug Pricing Pilot

November 8, 2026
The Biotechnology Innovation Organization is joining the legal fight against the Trump administration’s pilot program aimed at aligning drug prices in Medicare with prices charged in peer countries. BIO and two California-based biotech trade groups filed a complaint Friday in the U.S. District Court for the Northern District of California asserting that the Global Benchmark…
Research on cardiovascular health and treatments

Novartis Pelacarsen Fails to Lower Cardiovascular Events in Trial

November 8, 2026
Novartis’ experimental drug pelacarsen dramatically lowered lipoprotein(a) levels in a Phase 3 trial but failed to reduce serious cardiovascular outcomes. The HORIZON trial, which followed participants for nearly five years, showed no significant difference in heart attacks, strokes, urgent coronary revascularization, or deaths between those taking the drug and those on a placebo. This outcome…

Ongoing Cases